75 HAYDEN AVENUE, LEXINGTON, MA
Voyager Therapeutics Increases Authorized Shares to 245 Million
Other Events
Reports First Quarter 2026 Financial and Operating Results
Annual Report to Security Holders
CFO Departure - Nathan Jorgensen Resigns; Robin Swartz Appointed
Financial Results, Press Release
Material disclosure
Pivotal Year: Three Principal Pillars of Value Emerging in 2026
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order
SEC Staff Correspondence